Posted by Michael Wonder on 26 Sep 2017
European Commission approves Symtuza for the treatment of HIV-1 in adults and adolescents in Europe
26 September 2017 - Symtuza is the only darunavir-based single-tablet regimen approved for the treatment of HIV-1 in the European Union.
Janssen today announced that the European Commission has approved the use of Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg.
Cobicistat, emtricitabine and tenofovir alafenamide are from Gilead Sciences.
